IPO

Haymaker Acquisition Corp V secures $287.5M in its NYSE debut, highlighting how veteran sponsors are navigating a reformed blank-check market.

Amerant Bancorp's latest 7% senior note issuance reveals the steep but necessary cost of capital for mid-sized banks chasing aggressive regional growth.

ERShares' XOVR ETF offers retail investors a tantalizing glimpse into pre-IPO giants like SpaceX, but a closer look reveals a complex web of high rewards and risks.

Quebec-based Devonian Health Group plans a NYSE American debut, seeking U.S. capital to advance its promising pipeline of autoimmune disease treatments.

The firm's successful offering, featuring a striking 17% yield on Class A shares, signals strong investor appetite but also highlights the complex risks of split corps.

Premium Global Income Split Fund's latest offering boasts yields over 13%, but what are the risks hiding behind these impressive numbers? We break it down.

Utility giant Fortis just raised $1 billion with a complex debt instrument. We cut through the jargon to see what it means for your power and their future.

Target Hospitality navigates a major investor's exit with a concurrent $30M stock buyback, signaling confidence amid a significant ownership shift.

The Vancouver biotech is advancing a dual-targeting CAR and a safer STING therapy, betting that precision and strategy will pave its path to NASDAQ and beyond.

A century-old Hawaiian institution is going public. We look beyond the financials to see what ASB's Wall Street debut means for its community-first mission.

With profits doubling and a massive cash infusion, Mama's Creations is executing a masterclass in growth. But can its operational engine keep pace?

A top EV battery supplier just went public on the NYSE, but its real target is the AI boom. Can Londian Wason transform into a key player in NVIDIA's world?

Cabbacis is pitching its patented, very-low-nicotine hemp cigarettes to investors, betting its future on a proposed FDA rule to slash nicotine in tobacco.

Inflection Point’s latest SPAC closes a major IPO, but it’s not 2021. This is a story of seasoned players, mixed track records, and a hunt for real disruption.

Samsung Biologics is raising KRW 3 trillion to buy a peptide specialist and build a mega-campus. It's a bold play that trades short-term dilution for long-term dominance.

Fintech giant GCash is turning millions of everyday Filipinos into stock market investors, democratizing wealth and reshaping the nation's economic landscape.

JATT III Acquisition Corp's $60M IPO isn't just another SPAC. It’s a calculated bet by a proven team on the future of AI in drug discovery. But does it signal a new era for biotech M&A?

Estonian developer Hepsor AS is offering a 9.50% unsecured bond. We analyze if this high-yield opportunity is a strategic masterstroke or a risky wager.

Andersen Group insiders cashed out $216.8M in a secondary offering. The company saw no cash, but the move signals market confidence and reshapes its future.

A Boston biotech with Korean roots just went public in Seoul. Its goal: to repair the body's smallest blood vessels, a market Merck has already bet billions on.